Longeveron vs Outlook Therapeutics
Outlook Therapeutics reported revenue of $1 million in fiscal 2025, 1.2 times Longeveron's $1 million in fiscal 2025. Longeveron had an operating margin of -1942.2%, against -4744.2% at Outlook Therapeutics. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.
Side by side
| Longeveron | Outlook Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Sep 30, 2025 |
| Revenue | $1M | $1M |
| Revenue growth | −49.9% | — |
| Revenue growth a year, last 5 years | −26.5% | — |
| Gross margin | 67.0% | 4.0% |
| Operating margin | −1,942.2% | −4,744.2% |
| Net margin | −1,893.6% | −4,416.2% |
| Free cash flow | −$19M | — |
| Free cash flow margin | −1,575.5% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 86.8% | 87.6% |
| Last close | $1.82 | $0.40 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $7.9 million, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
LongeveronOutlook Therapeutics
Operating margin
Percent of revenue
LongeveronOutlook Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LongeveronOutlook Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Longeveron and Outlook Therapeutics pages.